caa a22 4500 445340622 CHVBK 20180317142811.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1007/s00436-011-2404-6 doi (NATIONALLICENCE)springer-10.1007/s00436-011-2404-6 Evaluation of the Therapeutic and Preventive Efficacy of 2.5 % Moxidectin [Elektronische Daten] 10 % Imidacloprid (Advocate®, Bayer Animal Health) in Dogs Naturally Infected or at Risk of Natural Infection by Dirofilaria repens / [Klaus Hellmann, Josef Heine, Gabriele Braun, Radmila Paran-Dobesova, Vlasta Svobodova] The objective of this GCP-compliant clinical field study was to evaluate the efficacy of the combination of moxidectin (minimum dose of 2.5mg/kg body weight) and imidacloprid (minimum dose of 10.0mg/kg body weight) spot-on (Advocate®) as a preventive and therapeutic treatment of natural infection by Dirofilaria repens in dogs in the Czech Republic. There were two arms of the study, both negatively controlled. 34 animals were randomly allocated to two groups of the treatment arm; 90 negative animals were randomly allocated to the prevention arm groups. All enrolled dogs were observed physically and blood was sampled monthly for Dirofilaria repens microfilaria counts for 18months by modified Knott test and PCR. 34 dogs were positive for microfilaria and enrolled in the treatment arm of this study (treated: 18, untreated: 16). The reduction of the log-transformed microfilaria counts was significantly higher in the treatment group on day 28 (p = 0.007), 56, 84 and 112 (p < 0.001). All animals treated were negative after a single treatment. In the untreated control group 93.75 % remained positive (p < 0.001). 87 dogs were negative for microfilaria prior to allocation to the "preventive” arm (treated: 49; untreated: 38; 3 excluded). One dog in the untreated control group became positive for Dirofliaria repens microfilaria, while none of the treated dogs became positive. Advocate® was effective in the treatment of dogs infected with microfilaria of Dirofilaria repens. Due to the low rate of natural infections the preventive efficacy could not be proven, but no dog treated became positive. The Author(s), 2011 Hellmann Klaus Klifovet AG, Munich, Germany aut Heine Josef Bayer Animal Health GmbH, Monheim, Germany aut Braun Gabriele Klifovet AG, Munich, Germany aut Paran-Dobesova Radmila Department of Pathological Morphology and Parasitology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic aut Svobodova Vlasta Department of Pathological Morphology and Parasitology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic aut Parasitology Research Springer-Verlag 109(2011-08-01), 77-86 0932-0113 109<77 2011 109 436 https://doi.org/10.1007/s00436-011-2404-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00436-011-2404-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hellmann Klaus Klifovet AG, Munich, Germany aut NATIONALLICENCE 700 1- Heine Josef Bayer Animal Health GmbH, Monheim, Germany aut NATIONALLICENCE 700 1- Braun Gabriele Klifovet AG, Munich, Germany aut NATIONALLICENCE 700 1- Paran-Dobesova Radmila Department of Pathological Morphology and Parasitology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic aut NATIONALLICENCE 700 1- Svobodova Vlasta Department of Pathological Morphology and Parasitology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic aut NATIONALLICENCE 773 0- Parasitology Research Springer-Verlag 109(2011-08-01), 77-86 0932-0113 109<77 2011 109 436 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer